Ko R, Shukuya T, Imamura C, Tokito T, Shimada N, Koyama R, Yamada K, Ishii H, Azuma K, Takahashi K. Phase I study of afatinib plus bevacizumab in patients with advanced non-squamous non-small cell lung cancer harboring EGFR mutations. Transl Lung Cancer Res., 2021;10(1): 183-192.
Miyawaki T, Wakuda K, Kenmotsu H, Miyawaki E, Mamesaya N, Kobayashi H, Omori S, Ono A, Naito T, Murakami H, Notsu A, Mori K, Harada H, Endo M, Ohde Y, Takahashi K, Takahashi T. Proposing Synchronous Oligometastatic Non-Small Cell Lung Cancer Based on Progression after First-line Systemic Therapy. Cancer Sci., 2021;112(1): 359-368.
Kato M, Sasaki S, Tateyama M, Arai Y, Motomura H, Sumiyoshi I, Ochi Y, Watanabe J, Ihara H, Togo S, Takahashi K. Clinical Significance of Continuable Treatment with Nintedanib Over 12 Months for Idiopathic Pulmonary Fibrosis in a Real-World Setting. Drug Design, Development and Therapy., 2021; 15: 223-230.
Miyashita Y, Ko R, Shimada N, Mitsuishi Y, Miura K, Matsumoto N, Asao T, Shukuya T, Shibayama R, Koyama R, Takahashi K. Impact of the generation of EGFR-TKIs administered as priortherapy on the effcacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation. Thoracic Cancer. 2021;12: 329-338.
Wakita M, Idei M, Saito K, Horiuchi Y, Yamatani K, Ishikawa S, Yamamoto T, Igawa G, Hinata M, Kadota K, Kurosawa T, Takahashi S, Saito T, Misawa S, Akazawa C, Naito T, Miida T, Takahashi K, Ai T, Tabe Y. Comparison of the clinical performance and usefulness of five SARS-CoV-2 antibody tests. PLoS One. 2021;16(2): e0246536.
Sumiyoshi I, Okabe T, Togo S, Takagi H, Motomura H, Ochi Y, Shimada N, Haraguchi M, Shibayama R, Fujimoto Y, Watanabe J, Iwai M, Kadoya K, Iwakami SI, Takahashi K. High lymphocyte population-related predictive factors for a long-term response in non-small cell lung cancer patients treated with pemetrexed: a retrospective observational study. J Transl Med., 2021; 19(1): 92.
Asahina H, Tanaka K, Morita S, Maemondo M, Seike M, Okamoto I, Oizumi S, Kagamu H, Takahashi K, Kikuchi T, Isobe T, Sugio K, Kobayashi K. A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced Non-Small-cell Lung Cancer: The OPAL Study (NEJ032C/LOGIK1801). Clin Lung Cancer., 2021; 22(2): 147-151.
Sekimoto Y, Suzuki K, Okura M, Hayashi T, Ebana H, Kumasaka T, Mitani K, Nishino K, Okamoto S, Kobayashi E, Takahashi K, Seyama K. Uncommon radiologic computed tomography appearances of the chest in patients with lymphangioleiomyomatosis. Sci Rep., 2021;11(1): 7170.
Hiki M, Tabe Y, Ai T, Matsue Y, Harada N, Sugimoto K, Matsushita Y, Matsushita M, Wakita M, Misawa S, Idei M, Miida T, Tamura N, Takahashi K. Naito T. Seroprevalence of anti-SARS-CoV-2 antibodies in Japanese COVID-19 patients. PLoS One., 2021;16(4): e0249449.
Udagawa H, Sugiyama E, Harada T, Atagi S, Koyama R, Watanabe S, Nakamura Y, Harada D, Hataji O, Tanaka F, Kida H, Satouchi M, Maeno K, Inoue A, Yoh K, Yamane Y, Urata Y, Yoshioka H, Yanaka T, Goto K. Bevacizumab plus platinum-based chemotherapy in advanced non-squamous non-small-cell lung cancer: a randomized, open-label phase 2 study (CLEAR) Transl Lung Cancer Res. 2021;10(7): 3059-3070.
Nishino K, Yoshimatsu Y, Muramatsu T, Sekimoto Y, Mitani K, Kobayashi E, Okamoto S, Ebana H, Okada Y, Kurihara M, Suzuki K, Inazawa J, Takahashi K, Watabe T, Seyama K. Isolation and characterisation of lymphatic endothelial cells from lung tissues affected by lymphangioleiomyomatosis. Sci Rep., 2021;11(1): 8406.
Nakamura IT, Ikegami M, Hasegawa N, Hayashi T, Ueno T, Kawazu M, Yagishita S, Goto Y, i Shinno Y, Kojima Y, Takamochi, Takahashi F, Takahashi K, Mano H, Kohsaka S. Development of an optimal protocol for molecular profiling of tumor cells in pleural effusions at single-cell level. Cancer Sci., 2021;112(5): 2006-2019.
Iwai M, Tulafu M, Togo S, Kawaji H, Kadoya K, Namba Y, Jin J, Watanabe J, Okabe T, Hidayat M, Sumiyoshi I, Itoh M, Koyama R, Ito Y, Orimo A, Takamochi K, Oh S, Suzuki K, Hayashizaki Y, Yoshida K, Takahashi K. Cancer-associated fibroblast migration in non-small cell lung cancers is modulated by increased integrin α11 expression. Mol Oncol., 2021;15(5): 1507-1527.
Tajima M, Togo S, Ko R, Koinuma Y, Sumiyoshi I, Torasawa M, Kikuchi N, Shiraishi A, Sasaki S, Kyogoku S, Kuwatsuru R, Takahashi K. CT Guided Needle Biopsy of Peripheral Lesions-Lesion Characteristics That May Increase the Diagnostic Yield and Reduce the Complication Rate. J Clin Med., 2021;10(9): 2031.
Okamoto S, Ebana H, Kurihara M, Mitani K, Kobayashi E, Hayashi T, Sekimoto Y, Nishino K, Otsuji M, Kumasaka T, Takahashi K, Seyama K. Folliculin haploinsufficiency causes cellular dysfunction of pleural mesothelial cells. Sci Rep., 2021;11(1): 10814.
Nurwidya F, Takahashi F, Winardi W, Tajima K, Mitsuishi Y, Murakami A, Kobayashi I, Nara T, Hashimoto M, Kato M, Hidayat M, Suina K, Hayakawa D, Asao T, Ko R, Shukuya T, Yae T, Shimada N, Yoshioka Y, Sasaki S, Takahashi K. Zinc-finger E-box-binding homeobox 1 (ZEB1) plays a crucial role in the maintenance of lung cancer stem cells resistant to gefitinib. Thorac Cancer., 2021;12(10): 1536-1548.
Sugiyama A, Shiota S, Yanagihara M, Nakayama H, Tsuiki S, Hayashida K, Inoue Y, Takahashi K. The role of long-term continuous positive airway pressure in the progression of obstructive sleep apnoea: A longitudinal cohort study. J Sleep Res., 2021;16: e13374.
Takeshige T, Harada N, Harada S, Ishimori A, Katsura Y, Sasano H, Sandhu Y, Matsuno K, Makino F, Ito J, Atsuta R, Akiba H, Takahashi K. Chitin induces steroid-resistant airway inflammation and airway hyperresponsiveness in mice. Allergol Int., 2021;70(3): 343-350.
Nakamura Takeda I, Kohsaka S, Ikegami M, Ikeuchi H, Ueno T, Li K, Beyett TS, Koyama T, Shimizu T, Yamamoto N, Takahashi F, Takahashi K, Eck MJ, Mano H. Comprehensive functional evaluation of variants of fibroblast growth factor receptor genes in cancer. NPJ Precis Oncol., 2021;5(1): 66.
Ohara K, Kinoshita S, Ando J, Azusawa Y, Ishii M, Harada S, Mitsuishi Y, Asao T, Tajima K, Yamamoto T, Takahashi F, Komatsu N, Takahashi K, Ando M. SCLC-J1, a novel small cell lung cancer cell line. Biochem Biophys Rep., 2021;27: 101089.
Fukuda H, Seyama K, Ito K, Ai T, Nojiri S, Hori S, Wakita M, Saito K, Shida Y, Nagura R, Hasegawa M, Kanemoto C, Tokuhara M, Okajima K, Yoshikawa Y, Katsuta N, Yamamoto T, Idei M, Horiuchi Y, Yamatani K, Misawa S, Naito T, Miida T, Sato H, Hattori N, Tabe Y, Takahashi K. Author Correction: SARS-CoV-2 seroprevalence in healthcare workers at a frontline hospital in Tokyo. Sci Rep., 2021;11(1): 16042.
Matsushita Y, Kusaoi M, Hiki M, Murayama G, Abe Y, Nozawa K, Takahashi K, Yamaji K, Tamura N, Naito T. Combination therapy with plasma exchange and glucocorticoid may be effective for severe COVID-19 infection: A retrospective observational study. Ther Apher Dial., 2021;25(4): 390-400.
Sakaue S, Kanai M, Tanigawa Y, Karjalainen J, Kurki M, Koshiba S, Narita A, Konuma T, Yamamoto K, Akiyama M, Ishigaki K, Suzuki A, Suzuki K, Obara W, Yamaji K, Takahashi K, Asai S, Takahashi Y, Suzuki T, Shinozaki N, Yamaguchi H, Minami S, Murayama S, Yoshimori K, Nagayama S, Obata D, Higashiyama M, Masumoto A, Koretsune Y; FinnGen, Ito K, Terao C, Yamauchi T, Komuro I, Kadowaki T, Tamiya G, Yamamoto M, Nakamura Y, Kubo M, Murakami Y, Yamamoto K, Kamatani Y, Palotie A, Rivas MA, Daly MJ, Matsuda K, Okada Y. A cross-population atlas of genetic associations for 220 human phenotypes. Nat Genet., 2021;53(10): 1415-1424.
Hasegawa N, Kohsaka S, Kurokawa K, Shinno Y, Nakamura IT, Ueno T, Kojima S, Kawazu M, Suehara Y, Ishijima M, Goto Y, Kojima Y, Yonemori K, Hayashi T, Saito T, Shukuya T, Takahashi F, Takahashi K, Mano H. Highly sensitive fusion detection using plasma cell-free RNA in non-small-cell lung cancers. Cancer Sci., 2021;112(10): 4393-4403.
Miyawaki T, Kenmotsu H, Yabe M, Kodama H, Nishioka N, Miyawaki E, Mamesaya N, Kobayashi H, Omori S, Wakuda K, Ono A, Deguchi S, Mitsuya K, Naito T, Murakami H, Mori K, Harada H, Hayashi N, Takahashi K, Takahashi T. Rechallenge with previously administered epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis. Invest New Drugs 2021;39(6): 1732-1741.
Miyawaki T, Kenmotsu H, Kodama H, Nishioka N, Miyawaki E, Mamesaya N, Kobayashi H, Omori S, Ko R, Wakuda K, Ono A, Naito T, Murakami H, Mori K, Harada H, Endo M, Takahashi K, Takahashi T. Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study. BMC Cancer., 2021;21(1): 1247.
Saito K, Ai T, Kawai A, Matsui J, Fukushima Y, Kikukawa N, Kyoutou T, Chonan M, Kawakami T, Hosaka Y, Misawa S, Takagi H, Matsushita Y, Hiki M, Okuzawa A, Hori S, Naito T, Miida T, Takahashi K, Tabe Y. Performance and usefulness of a novel automated immunoassay HISCL SARS-CoV-2 Antigen assay kit for the diagnosis of COVID-19. Sci Rep., 2021;11(1): 23196.
Katsuta N, Ito K, Fukuda H, Seyama K, Hori S, Shida Y, Nagura R, Nojiri S, Sato H. Elevated depressive symptoms among newer and younger healthcare workers in Japan during the COVID-19 pandemic. Neuropsychopharmacol Rep. 2021 Dec;41(4):544-547.
Takamochi K, Hara K, Hayashi T, Kohsaka S, Takahashi F, Suehara Y, Suzuki K. Programmed death-ligand 1 expression and its associations with clinicopathological features, prognosis, and driver oncogene alterations in surgically resected lung adenocarcinoma. Lung Cancer., 2021;61: 163-170.
Sano K, Hayashi T, Suehara Y, Hosoya M, Takamochi K, Kohsaka S, Kishikawa S, Kishi M, Saito S, Takahashi F, Kaneko K, Suzuki K, Yao T, Ishijima M, Saito T. Transcription start site-level expression of thyroid transcription factor 1 isoforms in lung adenocarcinoma and its clinicopathological significance. Journal of Pathology: Clinical Research., 2021;7(4): 361-374.
Hayashi T, Kohsaka S, Takamochi K, Kishikawa S, Sano K, Hara K, Suehara Y, Takahashi F, Saito T, Suzuki K, Yao T. Histological Characteristics of Lung Adenocarcinoma With Uncommon Actionable Alterations: Special Emphasis on MET exon 14 Skipping Alterations. Histopathology., 2021;78(7): 987-999.
Kishikawa S, Hayashi T, Saito T, Takamochi K, Kohsaka S, Sano K, Sasahara N, Sasa K, Kurihara T, Hara K, Suehara Y, Takahashi F, Suzuki K, Yao T. Diffuse expression of MUC6 defines a distinct clinicopathological subset of pulmonary invasive mucinous adenocarcinoma. Modern Pathology., 2021;34(4):786-797.
Nakagawara K, Namkoong H, Terai H, Masaki K, Tanosaki T, Shimamoto K, Lee H, Tanaka H, Okamori S, Kabata H, Chubachi S, Ikemura S, Kamata H, Yasuda H, Kawada I, Ishii M, Ishibashi Y, Harada S, Fujita T, Ito D, Bun S, Tabuchi H, Kanzaki S, Shimizu E, Fukuda K, Yamagami J, Kobayashi K, Hirano T, Inoue T, Kagyo J, Shiomi T, Ohgino K, Sayama K, Otsuka K, Miyao N, Odani T, Oyamada Y, Masuzawa K, Nakayama S, Suzuki Y, Baba R, Nakachi I, Kuwahara N, Ishiguro T, Mashimo S, Minematsu N, Ueda S, Manabe T, Funatsu Y, Koh H, Yoshiyama T, Saito F, Ishioka K, Takahashi S, Nakamura M, Goto A, Harada N, Kusaka Y, Nakano Y, Nishio K, Tateno H, Edahiro R, Takeda Y, Kumanogoh A, Kodama N, Okamoto M, Umeda A, Hagimura K, Sato T, Miyazaki N, Takemura R, Sato Y, Takebayashi T, Nakahara J, Mimura M, Ogawa K, Shimmura S, Negishi K, Tsubota K, Amagai M, Goto R, Ibuka Y, Hasegawa N, Kitagawa Y, Kanai T, Fukunaga K. Comprehensive and long-term surveys of COVID-19 sequelae in Japan, an ambidirectional multicentre cohort study: study protocol. BMJ Open Respir Res., 2021;8(1): e001015.
Tanaka H, Lee H, Morita A, Namkoong H, Chubachi S, Kabata H, Kamata H, Ishii M, Hasegawa N, Harada N, Ueda T, Ueda S, Ishiguro T, Arimura K, Saito F, Yoshiyama T, Nakano Y, Mutoh Y, Suzuki Y, Murakami K, Okada Y, Koike R, Kitagawa Y, Tokunaga K, Kimura A, Imoto S, Miyano S, Ogawa S, Kanai T, Fukunaga K, Japan C-TF. Clinical Characteristics of Patients with Coronavirus Disease (COVID-19): Preliminary Baseline Report of Japan COVID-19 Task Force, a Nationwide Consortium to Investigate Host Genetics of COVID-19. Int J Infect Dis., 2021;113: 74-81.
COVID-19 Host Genetics Initiative(Takahashi K, Harada N, Takagi H, Nakamura A, et al.). Mapping the human genetic architecture of COVID-19. Nature., 2021;600(7889): 472-477.
Kawaguchi K, Hashimoto M, Mikawa R, Asai A, Sato T, Sugimoto M. Protocol for assessing the senescence-associated lung pathologies. STAR Protoc. 2021 Dec 4;2(4):100993.
Fujimoto D, Miura S, Yoshimura K, Wakuda K, Oya Y, Yokoyama T, Yokoi T, Asao T, Tamiya M, Nakamura A, Yoshioka H, Haratani K, Teraoka S, Tokito T, Murakami S, Tamiya A, Itoh S, Yokouchi H, Watanabe S, Yamaguchi O, Tomii K, Yamamoto N. Pembrolizumab plus chemotherapy-induced pneumonitis in chemo-naïve patients with non-squamous non-small cell lung cancer: A multicentre, retrospective cohort study. Eur J Cancer., 2021;150: 63-72.
Miyawaki T, Kenmotsu H, Harada H, Ohde Y, Chiba Y, Haratani K, Okimoto T, Sakamoto T, Wakuda K, Ito K, Uemura T, Sakata S, Kogure Y, Nishimura Y, Nakagawa K, Yamamoto N. Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic non-small cell lung cancer TRAP OLIGO study (WJOG11118L). BMC Cancer. 2021 Oct 18;21(1):1121.
Wakuda K, Yabe M, Kodama H, Nishioka N, Miyawaki T, Miyawaki E, Mamesaya N, Kobayashi H, Omori S, Ono A, Kenmotsu H, Naito T, Murakami H, Shimizu T, Gon Y, Takahashi T. Long-term outcomes in extensive disease small cell lung cancer patients treated without immune checkpoint inhibitors. Jpn J Clin Oncol., 2021;51(12): 1736-1743.
Kodama H, Kenmotsu H, Kawabata T, Notsu A, Yabe M, Nishioka N, Miyawaki E, Miyawaki T, Mamesaya N, Kobayashi H, Omori S, Wakuda K, Ono A, Naito T, Murakami H, Takahashi T. Impact of angiogenesis inhibitor eligibility on the prognosis of patients with non-small cell lung cancer harboring EGFR mutation. Cancer Med., 2021;10(21): 7503-7513.
Omori S, Muramatsu K, Kawata T, Miyawaki E, Miyawaki T, Mamesaya N, Kawamura T, Kobayashi H, Nakashima K, Wakuda K, Ono A, Kenmotsu H, Naito T, Murakami H, Sugino T, Takahashi T. Trophoblast cell-surface antigen 2 expression in lung cancer patients and the effects of anti-cancer treatments. J Cancer Res Clin Oncol., 2021;17. doi: 10.1007/s00432-021-03784-3.
Mamesaya N, Muramatsu K, Yabe M, Kodama H, Nishioka N, Miyawaki T, Miyawaki E, Kobayashi H, Omori S, Wakuda K, Ono A, Kenmotsu H, Naito T, Murakami H, Harada H, Sugino T, Shimizu T, Gon Y, Takahashi T. Detection of programmed cell death-ligand 1 using 22C3 antibody in patients with unresectable stage III non-small cell lung cancer receiving chemoradiotherapy. Int J Clin Oncol. 2021 Apr;26(4):659-669.
Sakamoto S, Kataoka K, Kondoh Y, Kato M, Okamoto M, Mukae H, Bando M, Suda T, Yatera K, Tanino Y, Kishaba T, Hattori N, Taguchi Y, Saito T, Nishioka Y, Kuwano K, Kishi K, Inase N, Sasaki S, Takizawa H, Johkoh T, Sakai F, Homma S; Diffuse Lung Diseases Research Group of the Ministry of Health, Labour and Welfare, Japan. Pirfenidone plus inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomised trial. Eur Respir J., 2021;57: 2000348.
Hisata S, Bando M, Homma S, Kataoka K, Ogura T, Izumi S, Sakamoto S, Watanabe K, Saito Y, Shimizu Y, Kato M, Nishioka Y, Hara H, Waseda Y, Tanino Y, Yatera K, Hashimoto S, Mukae H, Inase N; Diffuse Lung Diseases Research Group of the Ministry of Health, Labour and Welfare, Japan. Safety and tolerability of combination therapy with pirfenidone and nintedanib for idiopathic pulmonary fibrosis: A multicenter retrospective observational study in Japan. Respir Investig., 2021;59(6): 819-826.
Nakagawa K, Kijima T, Okada M, Morise M, Kato M, Hirano K, Fujimoto N, Takenoyama M, Yokouchi H, Ohe Y, Hida T, Aoe K, Kishimoto T, Hirokawa M, Matsuki H, Kaneko Y, Yamada T, Morimoto C, Takeda M. Phase 2 Study of YS110, a Recombinant Humanized Anti-CD26 Monoclonal Antibody, in Japanese Patients With Advanced Malignant Pleural Mesothelioma. JTO Clin Res Rep., 2021;2(6): 100178.
Carrot-Zhang J, Soca-Chafre G, Patterson N, Thorner AR, Nag A, Watson J, Genovese G, Rodriguez J, Gelbard MK, Corrales-Rodriguez L, Mitsuishi Y, Ha G, Campbell JD, Oxnard GR, Arrieta O, Cardona AF, Gusev A, Meyerson M. Genetic Ancestry Contributes to Somatic Mutations in Lung Cancers from Admixed Latin American Populations. Cancer Discov., 2021;11(3): 591-598.
Kobayashi K, Terai H, Yasuda H, Hamamoto J, Hayashi Y, Takeuchi O, Mitsuishi Y, Masuzawa K, Manabe T, Ikemura S, Kawada I, Suzuki Y, Soejima K, Fukunaga K. Functional dissection of the KRAS G12C mutation by comparison among multiple oncogenic driver mutations in a lung cancer cell line model. Biochem Biophys Res Commun., 2021;534: 1-7.
Sueoka-Aragane N, Nakashima C, Yoshida H, Matsumoto N, Iwanaga K, Ebi N, Nishiyama A, Yatera K, Kuyama S, Fukuda M, Ushijima S, Umeguchi H, Harada D, Kashiwabara K, Suetsugu T, Fujimoto N, Tanaka F, Uramoto H, Yoshii C, Nakatomi K, Koh G, Seki N, Aoe K, Nosaki K, Inoue K, Takamori A, Kawaguchi A. The role of comprehensive analysis with circulating tumor DNA in advanced non-small cell lung cancer patients considered for osimertinib treatment. Cancer Med., 2021;10(12): 3873-3885.
Ikarashi D, Okimoto T, Shukuya T, Onagi H, Hayashi T, Sinicropi-Yao SL, Amann JM, Nakatsura T, Kitano S, Carbone DP. Comparison of Tumor Microenvironments Between Primary Tumors and Brain Metastases in Patients With NSCLC. JTO Clin Res Rep., 2021;2(10): 100230.
Sata M, Sasaki S, Oikado K, Saito Y, Tominaga J, Sakai F, Kato T, Iwasawa T, Kenmotsu H, Kusumoto M, Baba T, Endo M, Fujiwara Y, Sugiura H, Yanagawa N, Ito Y, Sakamoto T, Ohe Y, Kuwano K. Treatment and relapse of interstitial lung disease in nivolumab-treated patients with non-small cell lung cancer. Cancer Sci., 2021;112(4): 1506-1513.
Saito Y, Sasaki S, Oikado K, Tominaga J, Sata M, Sakai F, Kato T, Iwasawa T, Kenmotsu H, Kusumoto M, Baba T, Endo M, Fujiwara Y, Sugiura H, Yanagawa N, Ito Y, Sakamoto T, Ohe Y, Kuwano K. Radiographic features and poor prognostic factors of interstitial lung disease with nivolumab for non-small cell lung cancer. Cancer Sci., 2021;112(4): 1495-1505.
Shimoda Y, Yoshida T, Shirasawa M, Mizuno T, Jo H, Matsumoto Y, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Yamamoto N, Yatabe Y, Ohe Y, Motoi N. Smoking History Predicts High Presence of TILs and Efficacy of PD-1 Blockade in PD-L1 Expression-negative Non-small Cell Lung Cancer Patients. Anticancer Res., 2021;41(11): 5739-5747.
Takagi S, Sasaki Y, Koike S, Takemoto A, Seto Y, Haraguchi M, Ukaji T, Kawaguchi T, Sugawara M, Saito M, Funauchi Y, Ae K, Matsumoto S, Fujita N, Katayama R. Platelet-derived lysophosphatidic acid mediated LPAR1 activation as a therapeutic target for osteosarcoma metastasis. Oncogene., 2021;40(36): 5548-5558.
Harada N, Ito J, Takahashi K. Clinical effects and immune modulation of biologics in asthma. Respir Investig., 2021;59: 389-396.
Abe S, Ito J, Harada S, Sasano H, Ueda S, Sandhu Y, Takeshige T, Katsura Y,Harada N, Takahashi K. A case of hand urticaria, lip angioedema, and oropharyngeal pruritus induced by Japanese radish through IgE-mediated immediate allergic reaction. Allergy Asthma Clin Immunol. 2021; 17(1): 36.
Ueda S, Shukuya T, Hayashi T, Suzuki M, Kondo A, Aai Y, Takeshige T, Ninomiya H, Takahashi K. Transformation from adenocarcinoma to squamous cell lung carcinoma with MET amplification after lorlatinib resistance: A case report. Thorac Cancer., 2021;12(5): 715-719.
Miyashita Y, Hara M, Iwakami SI, Matsuda H, Iwakami N, Takahashi K. Sarcoidosis with marked necrosis in enlarged lymph nodes mimics mycobacterial infection: a case report. J Med Case Rep., 15(1):178, 2021
Matsuda H, Hara M, Iwakami S, Takahashi K. EML4-ALK positive lung adenocarcinoma with skeletal muscle metastasis in the right calf which was treatable with lorlatinib after resistance to treatment with alectinib. BMJ Case Rep., 2021;14(4): e240295.
Haraguchi M, Harada N, Watanabe J, Yoshikawa H, Shirai Y, Komura M, Koyama M, Ito J, Tsukune Y, Horimoto Y, Hayashi T, Nagaoka T, Uekusa T, Takahashi K. Disseminated nontuberculous mycobacteriosis and fungemia after second delivery in a patient with MonoMAC syndrome/GATA2 mutation: a case report. BMC Infect Dis., 2021;21(1): 502.
Kato M, Mori M, Miura K, Asao T, Motomura H, Nishino K, Ko R, Koyama R, Hayashi T, Takahashi K. Dramatic, significant metabolic response to a one-time pembrolizumab treatment following a relapse of pre-existing organizing pneumonia in a patient with advanced non-small cell lung cancer: A case report. Thorac Cancer., 2021; 12(22): 3076-3079.
Ishida M, Hiraoka M, Yaguchi A, Sugano K, Adachi N, Itoga T, Ishiguro T, Onishi H. Naldemedine-induced opioid withdrawal syndrome with severe psychiatric symptoms in an advanced cervical cancer patient without brain metastasis. Palliat Support Care., 27: 1-3, 2021
